Drug Discovery World

JANUARY 18, 2024

The results, together with the data from the recent LPS human challenge trial, further support the strategic expansion of the Phase II ready POLB 001 to treat and prevent cancer immunotherapy-induced CRS. million cases of cancer by 2030 1,2. Reductions were seen in all serum proinflammatory cytokines tested.

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162

Drug Discovery World

AUGUST 2, 2024

GLP-1 receptor agonist slows Alzheimer’s cognitive decline In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalisation after 12 weeks of treatment.

Clinical Trials 130

Clinical Trials Drugs Treatment Disease 130

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1.

Therapies 130

Therapies Clinical Trials Production Trials 130

Drug Discovery World

MAY 6, 2024

billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. The city is host to many innovative biotech companies, including relative newcomers Orexa, a company that recently launched its first Phase II clinical trial.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

Drug Discovery World

DECEMBER 7, 2023

The whitepaper ‘Guiding principles for drug discovery and development in amyotrophic lateral sclerosis’ outlines a consensus-based approach to de-risk clinical trials of novel therapeutics by an enhanced evidenced-based approach to pre-clinical studies. The Guiding Principles underpin a new £5 ($6.2)

Bioinformatics 130

Bioinformatics Drugs Clinical Trials Trials 130

Drug Discovery World

NOVEMBER 7, 2023

BASE director, Associate Professor Tim Mercer said the project will cement the facility’s footing in the growing mRNA industry, which was worth $55 billion in 2022 and tipped to grow to $107 billion globally by 2030. “We aim to begin manufacturing mRNA for Phase I clinical trials in 2024.”

Clinical Trials 130

Clinical Trials Government Vaccine Laboratories 130

Drug Discovery World

AUGUST 14, 2023

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. billion in 2020 to $15.5 billion 1.

Marketing 130

Marketing DNA Therapies FDA 130

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. The lengthy process adversely impacts clinical trial start-up time and trial costs.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

Drug Discovery World

JULY 31, 2023

DDW’s Reece Armstrong speaks to Hendrik Streefkerk , Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.

Clinical Trials 130

Clinical Trials Hospitals Therapies Trials 130

Drug Discovery World

MAY 22, 2023

PrecisionLife has also identified stratification biomarkers that can be used to recruit patients to clinical trials based on their mechanism of disease. By investing in collaborative projects LifeArc will deliver new tests, therapies and other medical technologies with the ultimate goal of making MND treatable by 2030.

Disease 130

Disease Clinical Trials Laboratories Treatment 130

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. The pivotal trials are evaluating gantenerumab in more than 2,000 participants for more than two years and are expected to be completed in the second half of 2022.

Disease 52

Disease Therapies FDA Trials 52

Vial

MAY 20, 2024

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030.

Clinical Research 52

Clinical Research Research Clinical Trials Laboratories 52

The Pharma Data

JULY 15, 2021

Trial will include participants at risk for cognitive and functional decline related to Alzheimer’s disease. TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Clinical Trials Therapies Disease 52

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Additional trials (e.g.,

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Drug Discovery World

JANUARY 2, 2024

She believes we might start to see a combination of vaccines with other immunotherapies or classical therapies out there, and that this will become more and more prevalent because of the nature of cancer. As for Infinitopes, the company’s trials will begin in 2024. That’s exactly what we’ve done.

Research 147

Research Vaccine Science Trials 147

DrugBank

MARCH 7, 2024

adults using obesity medications by 2030, further underlining the growing significance of this sector. On the other hand, Amgen revealed early-stage trial data on a promising once-a-month, weight loss medication, signaling its entry into this competitive arena. Goldman Sachs analysts anticipate a significant rise in the number of U.S.

Pharmaceutical Companies 82

Pharmaceutical Companies Pharmaceuticals Clinical Trials Pharmacokinetics 82

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020 3.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

OCTOBER 9, 2021

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies. trillion per space by 2030.

Disease 52

Disease FDA Therapies Testimonials 52

Drug Discovery World

DECEMBER 12, 2022

Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening to read in the Guardian 1 that the NHS in the UK believes that by 2030 there will be no new cases of HIV in England. In Nature 3 , we learnt about the CRISPR cancer trial success leading the way to personalised treatments.

Drugs 130

Drugs Engineering Clinical Trials Science 130

DrugBank

MARCH 15, 2024

billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. billion, Mounjaro's performance is a testament to the booming demand for innovative therapies targeting diabetes and obesity.  With sales soaring to $2.2

Pharmaceutical Companies 69

Pharmaceutical Companies Pharmaceuticals Treatment Marketing 69

Drug Discovery World

APRIL 10, 2024

An ICON survey of over 100 drug development professionals in obesity research revealed optimism about future therapies, with a significant shift towards combination treatments for obesity and its comorbidities.

Clinical Trials 130

Clinical Trials Trials Therapies Treatment 130

The Pharma Data

NOVEMBER 1, 2020

The trial is expected to enroll 160 patients. billion by 2030 2. I am very delighted to learn the swift IND clearance by the US FDA, and we are initiating the phase II clinical trial immediately,” said Dr. Jasmine Cui, the co-founder, chairman, and Chief Executive Officer of InnoCare. About InnoCare Pharma.

Clinical Trials 52

Clinical Trials FDA Trials Treatment 52

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”

Therapies 40

Therapies Trials Treatment Disease 40

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. It is approved in the U.S.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

The Pharma Data

MARCH 13, 2021

“Tau has become increasingly validated as a predictive biomarker for Alzheimer’s disease progression, as shown again in this trial,” said Liana G. Patients with treatment discontinuations were allowed to continue in the trial. Apostolova, M.D., In the donanemab arm, 30.5 trailblazer2study.com. Source link:[link].

Disease 40

Disease Trials Treatment Medical Schools 40

Drug Discovery World

FEBRUARY 10, 2023

This is reflected in the government’s aim of becoming a leader in the ATMP space by 2030. Magnus Persson is a physician and scientist with a background in both academia and industry, working for the likes of Sanofi on clinical trials activities and across venture capital firms in the US. It’s also a seal of quality.

Science 130

Science Drugs Pharmaceutical Companies Pharmaceuticals 130

The Pharma Data

MARCH 9, 2021

Additional data highlight Lilly’s AD program focused on developing both disease-modifying therapies that slow clinical progression by targeting the underlying causes of AD and novel diagnostics and biomarkers to enable a timely and more accurate diagnosis. About Avid Radiopharmaceuticals.

Disease 40

Disease International Research Therapies 40

The Pharma Data

JULY 29, 2021

Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. In June 2021, Lilly announced the U.S. vice president of pain and neurodegeneration, Lilly.

Disease 52

Disease Pharmacokinetics Treatment FDA 52

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies. Strong pipeline with robust late-stage development program and broad potential across indications.

Small Molecule 52

Small Molecule Clinical Trials Clinical Development Production 52

The Pharma Data

MAY 3, 2021

This includes making COVID-19 therapies available in low- and middle-income countries, as well as hurricane preparedness in the U.S. Lilly ‘s commitment also supports Lilly 30×30, the company’s goal to improve access to quality health care for 30 million people living in settings with limited resources, each year, by 2030.

Clinical Trials 40

Clinical Trials Disease Therapies Trials 40

DrugBank

AUGUST 9, 2024

Moreover, the probability of success for a drug candidate entering clinical trials is only around 10%, highlighting the substantial risks involved. In 2021, an estimated 537 million adults were living with diabetes, a number projected to reach 643 million by 2030. billion by 2030. billion in 2021, is projected to reach 231.7

Pharmaceuticals 78

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 78

Drug Discovery World

MARCH 14, 2023

As for haemorrhagic stroke, GlobalData forecasts suggest that the incidence rates in the US were 0.02% in 2022 and are predicted to rise to 0.03% by 2030. The Phase II/III ADVANCE clinical trial of lead candidate, leriglitazone, published in The Lancet Neurology , did not meet the primary outcome for the six-minute walk test.

Science 130

Science Disease RNA Clinical Trials 130

Drug Discovery World

JANUARY 19, 2023

This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). billion by 2030 (BioSpace, 11 August 2022). billion by 2030 (BioSpace, 11 August 2022).

DNA 130

DNA Therapies Assay Development Production 130

Drug Discovery World

APRIL 12, 2023

In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 2030 1. Food and Drug Administration (FDA) for the adjuvant treatment of patients with high-risk melanoma following complete resection.

Vaccine 130

Vaccine Immune Response RNA DNA 130

Drug Discovery World

FEBRUARY 15, 2023

Existing therapies have been focused on eliminating the cancer cells and/or on preventing its progression by using a combination of chemotherapy, radiotherapy, and surgical approaches. Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4.

Research 130

Research Therapies Immune Response Clinical Trials 130

Drug Discovery World

AUGUST 8, 2023

In the global pharmaceuticals market, India ranks third worldwide for production by volume and the domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 1. India will make its mark as a growing market, potential competitor or partner in manufacturing and R&D, and as a location for clinical trials.”

Research 130

Research Pharmacy Pharmaceuticals Government 130

Drug Discovery World

JUNE 26, 2023

Now, there are many mRNA-based therapeutics in clinical development and mRNA cancer vaccines have been promised by 2030. In rare diseases, Moderna has several mRNA therapeutics in clinical development, including one in Phase II, a treatment for Propionic acidemia (PA), for which the company recently announced encouraging trial results.

Vaccine 130

Vaccine Virus Clinical Trials Trials 130